Industry Focus

Industry Focus

Healthcare: Should You Stick With Gilead Sciences?

Informações:

Añadir a la estante
Escucha
muestra
Escucha

Sinopsis

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD

Show more